Evolent Health, Inc. (EVH)
NYSE: EVH · Real-Time Price · USD
9.43
-0.17 (-1.77%)
Mar 31, 2025, 9:47 AM EDT - Market open
Evolent Health Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Evolent Health stock have an average target of 16.71, with a low estimate of 12 and a high estimate of 35. The average target predicts an increase of 77.20% from the current stock price of 9.43.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Evolent Health stock from 14 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 6 | 6 | 6 |
| Buy | 6 | 6 | 6 | 6 | 7 | 7 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 13 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $13 → $12 | Buy | Maintains | $13 → $12 | +27.25% | Mar 10, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Maintains $13 → $12 | Buy | Maintains | $13 → $12 | +27.25% | Feb 24, 2025 |
| Piper Sandler | Piper Sandler | Buy Reiterates $17 → $16 | Buy | Reiterates | $17 → $16 | +69.67% | Feb 21, 2025 |
| Needham | Needham | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +59.07% | Feb 21, 2025 |
| JMP Securities | JMP Securities | Buy Reiterates $12 | Buy | Reiterates | $12 | +27.25% | Feb 14, 2025 |
Financial Forecast
Revenue This Year
2.13B
from 2.55B
Decreased by -16.59%
Revenue Next Year
2.45B
from 2.13B
Increased by 15.02%
EPS This Year
0.58
from -0.81
EPS Next Year
0.82
from 0.58
Increased by 42.60%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.7B | 3.0B | 3.3B | ||
| Avg | 2.1B | 2.5B | 2.8B | ||
| Low | 2.0B | 2.3B | 2.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.3% | 40.8% | 34.8% | ||
| Avg | -16.6% | 15.0% | 15.1% | ||
| Low | -22.9% | 5.6% | 1.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 0.91 | 1.36 | 1.86 | ||
| Avg | 0.58 | 0.82 | 1.79 | ||
| Low | -0.04 | 0.18 | 1.73 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 135.9% | 126.5% | ||
| Avg | - | 42.6% | 117.8% | ||
| Low | - | -69.3% | 111.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.